Frontiers in Oncology | Thoracic Oncology

Clinical Trial

Published on 14 Oct 2014

A Multicenter Pilot Study Examining the Role of Circulating Tumor Cells as a Blood-Based Tumor Marker in Patients with Extensive Small-Cell Lung Cancer

in Thoracic Oncology

Chao H. Huang
Jo A. Wick
Gurusingham Sitta Sittampalam
Victor Sanjit Nirmalanandhan
Apar Kishor Ganti
Prakash C. Neupane
Stephen K. Williamson
Andrew K. Godwin
Sarah Schmitt
Nora J. Smart

Frontiers in Oncology

doi 10.3389/fonc.2014.00271

6,971 views
31 citations

Mini Review

Published on 13 Oct 2014

Role of Radiotherapy in Metastatic Non-Small Cell Lung Cancer

in Thoracic Oncology

Sergio L. Faria

Frontiers in Oncology

doi 10.3389/fonc.2014.00229

9,873 views
13 citations

Mini Review

Published on 29 Sep 2014

Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer

in Thoracic Oncology

Barbara Melosky

Frontiers in Oncology

doi 10.3389/fonc.2014.00256

12,180 views
20 citations

Original Research

Published on 29 Sep 2014

Hidden Treasures in “Ancient” Microarrays: Gene-Expression Portrays Biology and Potential Resistance Pathways of Major Lung Cancer Subtypes and Normal Tissue

in Thoracic Oncology

Konstantinos Kerkentzes
Vincenzo Lagani
Ioannis Tsamardinos
Mogens Vyberg
Oluf Dimitri Røe

Frontiers in Oncology

doi 10.3389/fonc.2014.00251

8,500 views
18 citations

Mini Review

Published on 22 Sep 2014

Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine

in Thoracic Oncology

Donna M. Graham
Natasha B. Leighl

Frontiers in Oncology

doi 10.3389/fonc.2014.00258

5,561 views
5 citations

Mini Review

Published on 22 Sep 2014

Optimizing Tissue Sampling for the Diagnosis, Subtyping, and Molecular Analysis of Lung Cancer

in Thoracic Oncology

Linda Marie Ofiara
Asma Navasakulpong
Stephane Beaudoin
Anne Valerie Gonzalez

Frontiers in Oncology

doi 10.3389/fonc.2014.00253

12,850 views
40 citations

Review

Published on 16 Sep 2014

Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs

in Thoracic Oncology

Barbara Melosky
Vera Hirsh

Frontiers in Oncology

doi 10.3389/fonc.2014.00238

15,745 views
69 citations

Mini Review

Published on 15 Sep 2014

The Management of Brain Metastases in Non-Small Cell Lung Cancer

in Thoracic Oncology

Scott Owen
Luis Souhami

Frontiers in Oncology

doi 10.3389/fonc.2014.00248

59,168 views
68 citations

Mini Review

Published on 15 Sep 2014

Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials

in Thoracic Oncology

Barbara Melosky

Frontiers in Oncology

doi 10.3389/fonc.2014.00244

14,378 views
62 citations

Mini Review

Published on 04 Sep 2014

Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System

in Thoracic Oncology

Anna Truini
Angela Alama
Maria Giovanna Dal Bello
Simona Coco
Irene Vanni
Erika Rijavec
Carlo Genova
Giulia Barletta
Federica Biello
Francesco Grossi

Frontiers in Oncology

doi 10.3389/fonc.2014.00242

18,994 views
75 citations

Mini Review

Published on 27 Aug 2014

Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies – Past, Present, and Future

in Thoracic Oncology

Johanna N. Spaans
Glenwood D. Goss

Frontiers in Oncology

doi 10.3389/fonc.2014.00233

9,441 views
18 citations

Mini Review

Published on 19 Aug 2014

Maintenance Therapies for Non-Small Cell Lung Cancer

in Thoracic Oncology

Normand Blais
Elie Kassouf

Frontiers in Oncology

doi 10.3389/fonc.2014.00213

7,214 views
16 citations

Mini Review

Published on 11 Aug 2014

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS

in Thoracic Oncology

Grzegorz J. Korpanty
Donna M. Graham
Mark D. Vincent
Natasha B. Leighl

Frontiers in Oncology

doi 10.3389/fonc.2014.00204

51,772 views
170 citations

Mini Review

Published on 30 Jul 2014

Collaborative Care in NSCLC; the Role of Early Palliative Care

in Thoracic Oncology

Marnie Howe
Ronald L. Burkes

Frontiers in Oncology

doi 10.3389/fonc.2014.00192

5,908 views
8 citations

Mini Review

Published on 23 Jul 2014

Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung Cancer

in Thoracic Oncology

Johanna N. Spaans
Glenwood D. Goss

Frontiers in Oncology

doi 10.3389/fonc.2014.00190

8,062 views
60 citations

Mini Review

Published on 21 Jul 2014

A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer

in Thoracic Oncology

Khashayar Esfahani
Jason Scott Agulnik
Victor Cohen

Frontiers in Oncology

doi 10.3389/fonc.2014.00174

10,648 views
25 citations

Mini Review

Published on 21 Jul 2014

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)

in Thoracic Oncology

Normand Blais
Vera Hirsh

Frontiers in Oncology

doi 10.3389/fonc.2014.00177

10,989 views
7 citations

Mini Review

Published on 16 Jul 2014

Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist’s Perspective

in Thoracic Oncology

Elisa Brega
Guilherme Brandao

Frontiers in Oncology

doi 10.3389/fonc.2014.00182

9,269 views
20 citations

Mini Review

Published on 10 Jul 2014

The Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly: An Evidence-Based Approach

in Thoracic Oncology

David E. Dawe
Peter Michael Ellis

Frontiers in Oncology

doi 10.3389/fonc.2014.00178

7,937 views
13 citations

Mini Review

Published on 03 Jul 2014

Is the Evaluation of Quality of Life in NSCLC Trials Important? Are the Results to be Trusted?

in Thoracic Oncology

Vera Hirsh

Frontiers in Oncology

doi 10.3389/fonc.2014.00173

4,608 views
10 citations

Mini Review

Published on 27 Jun 2014

Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line

in Thoracic Oncology

Abdulaziz Al-Farsi
Peter Michael Ellis

Frontiers in Oncology

doi 10.3389/fonc.2014.00157

11,868 views
45 citations

Review

Published on 16 Jun 2014

Targeted Treatments of Bone Metastases in Patients with Lung Cancer

in Thoracic Oncology

Vera Hirsh

Frontiers in Oncology

doi 10.3389/fonc.2014.00146

11,553 views
10 citations

General Commentary

Published on 07 May 2014

Novel Biologic Therapies for Thymic Epithelial Tumors

in Thoracic Oncology

Yuanbin Chen
Helen Gharwan
Anish Thomas

Frontiers in Oncology

doi 10.3389/fonc.2014.00103

5,373 views
11 citations

Review

Published on 14 Jan 2014

Surgical Approaches for Stage IVA Thymic Epithelial Tumors

in Thoracic Oncology

Mark Shapiro
Robert J Korst

Frontiers in Oncology

doi 10.3389/fonc.2013.00332

7,259 views
21 citations

1,913 articles

articles

A Multicenter Pilot Study Examining the Role of Circulating Tumor Cells as a Blood-Based Tumor Marker in Patients with Extensive Small-Cell Lung Cancer

Role of Radiotherapy in Metastatic Non-Small Cell Lung Cancer

Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer

Hidden Treasures in “Ancient” Microarrays: Gene-Expression Portrays Biology and Potential Resistance Pathways of Major Lung Cancer Subtypes and Normal Tissue

Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine

Optimizing Tissue Sampling for the Diagnosis, Subtyping, and Molecular Analysis of Lung Cancer

Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs

The Management of Brain Metastases in Non-Small Cell Lung Cancer

Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials

Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System

Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies – Past, Present, and Future

Maintenance Therapies for Non-Small Cell Lung Cancer

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS

Collaborative Care in NSCLC; the Role of Early Palliative Care

Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung Cancer

A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)

Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist’s Perspective

The Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly: An Evidence-Based Approach

Is the Evaluation of Quality of Life in NSCLC Trials Important? Are the Results to be Trusted?

Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line

Targeted Treatments of Bone Metastases in Patients with Lung Cancer

Novel Biologic Therapies for Thymic Epithelial Tumors

Surgical Approaches for Stage IVA Thymic Epithelial Tumors